徐岩

研究助理教授

教育背景

博士后(清华大学)

博士(吉林大学)

学士(吉林大学)

研究领域
药物分子设计、新药发现、化学生物学
电子邮件
yanxu@cuhk.edu.cn
个人简介

徐岩博士于2010年-2013年在美国纽约州立大学上州医科大学从事博士研究工作,2013年在吉林大学药学院获得分子生物学和生物化学博士学位,2013年-2018年在清华大学生命科学学院从事博士后研究工作。自2019年1月起,徐岩博士任职于香港中文大学(深圳)生命与健康科学学院并担任研究助理教授。

徐岩博士主要从事药物分子设计和新药发现的研究工作,主要研究内容包括基于蛋白-蛋白相互作用的配体分子设计,计算机辅助药物设计,药物筛选与优化等。徐岩博士的研究关注在使用多种不同学科的工具,针对疾病相关的蛋白-蛋白相互作用靶点,设计与发现新型生物活性分子,可用于研究蛋白相互作用机理的化学探针,或作为治疗肿瘤、传染病和神经退行性疾病的潜在药物。

学术著作

1. Tian W, Xu Y, Han X, Duggineni S, Han X, Huang Z and An J. Development of a novel fluorescence polarization-based assay for studying the β-catenin/Tcf4 interaction. J. Biomol. Screen., 2012, 17(4):530-4.
2. Choi WT, Duggineni S, Xu Y, Huang Z and An J. Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4). J. Med. Chem., 2012, 9; 55(3):977-94.
3. Dong CZ, Tian S, Choi WT, Kumar S, Liu D, Xu Y, Han X, Huang Z and An J. Critical role in CXCR4 signaling and internalization of the polypeptide main chain in the amino terminus of SDF-1α probed by novel N-methylated synthetically and modularly modified chemokine analogues. Biochemistry, 2012, 31; 51(30):5951-7.
4. Tian W, Han X, Yan M, Xu Y, Duggineni S, Lin N, Luo G, Li YM, Han X, Huang Z and An J. Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction. Biochemistry, 2012, 17; 51(2):724-31.
5. Duggineni S, Mitra S, Noberini R, Han X, Lin N, Xu Y, Tian W, An J, Pasquale EB and Huang Z. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Biochem. Pharmacol., 2013, 15; 85(4):507-13.
6. Xu Y, Duggineni S, Espitia S, Richman DD, An J and Huang Z. A synthetic bivalent ligand of CXCR4 inhibits HIV infection. Biochem. Biophys. Res. Commun., 2013, 435(4):646-50.
7. Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, An J, Pasquale EB and Huang Z. Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor. ACS Med Chem Lett., 2013, 5;4(3).
8. Han X, Xu Y, Yang Y, Xi J, Tian W, Duggineni S, Huang Z and An J. Discovery and characterization of a novel cyclic peptide that effectively inhibits ephrin binding to the EphA4 receptor and displays anti-angiogenesis activity. PLoS One., 2013, 12;8(11):e80183.
9. Zhu Y, Yang S, Juan W, Mao Y, Xu Y*, An J and Huang Z. LC–MS/MS assay for the determination of a novel D-peptide antagonist of CXCR4 in rat plasma and its application to a preclinical pharmacokinetic. J. Pharm. Biomed. Anal., 2018, 161: 159-167.
10. Mao Y, Meng Q, Song P, Zhu S, Xu Y, Snyder E, An J and Huang Z. Novel Bivalent and D-Peptide Ligands of CXCR4 Mobilize Hematopoietic Progenitor Cells to the Blood in C3H/HeJ Mice. Cell Transplantation, 2018, 27(8):1249-1255.
11. Zhang H, Fang X, Meng Q, Mao Y, Xu Y, Fan T, An J and Huang Z. Design, synthesis and characterization of new potent microtubule inhibitors with dual anti-proliferative and anti-angiogenic activities. Euro. J. Med. Chem., 2018, 157:380-396.